NIH awards $3.8 million to predict dementia in patients with Parkinson's disease

NewsGuard 100/100 Score

The National Institute of Neurological Disorders and Stroke at the National Institutes of Health (NIH) has awarded a grant expected to total $3.8 million to Virendra Mishra, Ph.D., associate staff at Cleveland Clinic Lou Ruvo Center for Brain Health, to identify biomarkers - or disease indicators - to predict dementia in patients with Parkinson's disease.

Although dementia affects approximately 50-80% of those living with Parkinson's disease within 12 years of diagnosis, currently there are no means for predicting dementia in specific individuals. The possibility of identifying who will develop dementia with Parkinson's disease progression has several clinical benefits, including providing individuals with greater clarity on their future and helping clinicians better manage disease progression."

Virendra Mishra, Ph.D., associate staff at Cleveland Clinic Lou Ruvo Center for Brain Health

The five-year grant supports the project, "Towards Generating a Multimodal and Multivarate Classification Model from Imaging and Non-Imaging Measures for Accurate Diagnosis and Monitoring of Dementia in Parkinson's Disease," which will use biomarkers spanning imaging, blood, cerebrospinal fluid and genetics to develop a predictive mathematical model to identify specific individuals with Parkinson's disease who may develop dementia as their disease progresses.

Utilizing sophisticated and pathologically relevant neuroimaging measures -- such as diffusion-weighted MRI and resting state functional MRI -- with non-imaging measures, including clinical data, demographics, genetics and cerebrospinal fluid, Mishra aims to:

* Understand how functional brain connectivity (interaction between different brain regions to complete the task at hand) and structural brain connectivity (information flow between brain regions responsible for completing the task at hand) differ in dementia in Parkinson's disease

* Identify the best biomarkers that predict dementia in Parkinson's disease through multivariate statistical modelling

Through this research, Mishra plans to develop a method that can be applied in clinical care with a greater-than-chance success rate to improve patient outcomes. In addition to clinical implications, identifying pathophysiology-based biomarkers for dementia in Parkinson's disease is critical for selecting appropriate individuals for participation in clinical trials of potential new disease-modifying therapies, and better understanding of the underlining pathophysiological processes.

Additionally, the novel imaging techniques developed for this research also can be applied in other neurodegenerative diseases such as Alzheimer's disease to help advance the understanding of disease-specific neuroanatomical changes indicative of dementia.

This project is supported by NIH grant award R01NS117547.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Antipsychotics for dementia associated with elevated risks of serious adverse outcomes